Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

The association of profilin-1 levels with survival in chronic kidney disease.

Eroglu E, Unal HU, Guclu A, Kocyigit I, Karaman M, Saglam M, Gezer M, Tas A, Zararsiz G, Eyileten T, Aydin İ, Oguz Y, Gungor O, Yilmaz MI.

Eur J Clin Invest. 2017 Dec;47(12). doi: 10.1111/eci.12839. Epub 2017 Oct 27.

PMID:
28981140
2.

IL-33 and ST2 levels in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events, and survival.

Gungor O, Unal HU, Guclu A, Gezer M, Eyileten T, Guzel FB, Altunoren O, Erken E, Oguz Y, Kocyigit I, Yilmaz MI.

PLoS One. 2017 Jun 14;12(6):e0178939. doi: 10.1371/journal.pone.0178939. eCollection 2017.

3.

A different scintigraphic approach to evaluate the glomerular filtration rate.

Haciosmanoglu T, Karacalioglu AO, Eyileten T, Ince S, Arslan N.

Rev Esp Med Nucl Imagen Mol. 2017 Sep - Oct;36(5):275-284. doi: 10.1016/j.remn.2017.01.015. Epub 2017 Mar 29. English, Spanish.

PMID:
28363505
4.

Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival.

Kanbay M, Afsar B, Siriopol D, Unal HU, Karaman M, Saglam M, Gezer M, Taş A, Eyileten T, Guler AK, Aydin İ, Oguz Y, Tarim K, Covic A, Yilmaz MI.

Eur J Intern Med. 2016 Sep;33:81-7. doi: 10.1016/j.ejim.2016.06.033. Epub 2016 Jul 7.

PMID:
27394925
5.

Thyroid function and cardiovascular events in chronic kidney disease patients.

Afsar B, Yilmaz MI, Siriopol D, Unal HU, Saglam M, Karaman M, Gezer M, Sonmez A, Eyileten T, Aydin I, Hamcan S, Oguz Y, Covic A, Kanbay M.

J Nephrol. 2017 Apr;30(2):235-242. doi: 10.1007/s40620-016-0300-y. Epub 2016 Apr 2.

PMID:
27039198
6.

Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events.

Yilmaz MI, Siriopol D, Saglam M, Unal HU, Karaman M, Gezer M, Kilinc A, Eyileten T, Guler AK, Aydin İ, Vural A, Oguz Y, Covic A, Ortiz A, Kanbay M.

Calcif Tissue Int. 2016 Aug;99(2):121-30. doi: 10.1007/s00223-016-0136-4. Epub 2016 Mar 26.

PMID:
27016924
7.

Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.

Kanbay M, Afsar B, Siriopol D, Unal HU, Karaman M, Saglam M, Eyileten T, Gezer M, Verim S, Oguz Y, Vural A, Ortiz A, Johnson RJ, Covic A, Yilmaz MI.

Int Urol Nephrol. 2016 Jul;48(7):1129-36. doi: 10.1007/s11255-016-1271-6. Epub 2016 Mar 23.

PMID:
27007614
8.

The Relationship Between Plasma Whole Blood Viscosity and Cardiovascular Events in Patients With Chronic Kidney Disease.

Celik T, Yilmaz MI, Balta S, Ozturk C, Unal HU, Aparci M, Karaman M, Demir M, Yildirim AO, Saglam M, Kilic S, Eyileten T, Aydin İ, Iyisoy A.

Clin Appl Thromb Hemost. 2017 Sep;23(6):663-670. doi: 10.1177/1076029616634888. Epub 2016 Feb 22.

PMID:
26907084
9.

Serum neutrophil gelatinase-associated lipocalin is associated with cardiovascular events in patients with chronic kidney disease.

Solak Y, Yilmaz MI, Siriopol D, Saglam M, Unal HU, Yaman H, Gok M, Cetinkaya H, Gaipov A, Eyileten T, Sari S, Yildirim AO, Tonbul HZ, Turk S, Covic A, Kanbay M.

Int Urol Nephrol. 2015 Dec;47(12):1993-2001. doi: 10.1007/s11255-015-1136-4. Epub 2015 Oct 26.

PMID:
26498629
10.

The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.

Sonmez A, Yilmaz MI, Saglam M, Unal HU, Gok M, Cetinkaya H, Karaman M, Haymana C, Eyileten T, Oguz Y, Vural A, Rizzo M, Toth PP.

Lipids Health Dis. 2015 Apr 16;14:29. doi: 10.1186/s12944-015-0031-4.

11.

A longitudinal study of inflammation, CKD-mineral bone disorder, and carotid atherosclerosis after renal transplantation.

Yilmaz MI, Sonmez A, Saglam M, Cayci T, Kilic S, Unal HU, Karaman M, Cetinkaya H, Eyileten T, Gok M, Oguz Y, Vural A, Mallamaci F, Zoccali C.

Clin J Am Soc Nephrol. 2015 Mar 6;10(3):471-9. doi: 10.2215/CJN.07860814. Epub 2014 Dec 26.

12.

Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.

Yilmaz MI, Sonmez A, Saglam M, Kurt YG, Unal HU, Karaman M, Gok M, Cetinkaya H, Eyileten T, Oguz Y, Vural A, Mallamaci F, Zoccali C.

Am J Nephrol. 2014;40(3):208-14. doi: 10.1159/000366169. Epub 2014 Oct 10.

13.

Mitral annular calcification and the serum osteocalcin level in patients with chronic kidney disease.

Unal HU, Çelik M, Gökoğlan Y, Çetinkaya H, Gök M, Karaman M, Yilmaz Mİ, Eyileten T, Oğuz Y.

Ren Fail. 2014 Nov;36(10):1481-5. doi: 10.3109/0886022X.2014.962421. Epub 2014 Sep 16.

PMID:
25224152
14.

Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.

Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, Karaman M, Unal HU, Oguz Y, Sari S, Eyileten T, Goldsmith D, Vural A, Veisa G, Covic A, Yilmaz MI.

J Clin Endocrinol Metab. 2014 Oct;99(10):E1854-61. doi: 10.1210/jc.2014-2042. Epub 2014 Jul 24.

PMID:
25057883
15.

Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease.

Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU, Eyileten T, Gok M, Cetinkaya H, Oguz Y, Sari S, Vural A, Mititiuc I, Covic A, Kanbay M.

Kidney Int. 2014 Dec;86(6):1213-20. doi: 10.1038/ki.2014.227. Epub 2014 Jul 2.

16.

Endothelial function in patients with familial Mediterranean fever-related amyloidosis and association with cardiovascular events.

Yilmaz MI, Demirkaya E, Acikel C, Saldir M, Akar S, Cayci T, Saglam M, Unal HU, Gok M, Polat A, Cetinkaya H, Eyileten T, Sari S, Yildirim AO, Sonmez A, Oguz Y, Vural A, Ozen S, Carrero JJ.

Rheumatology (Oxford). 2014 Nov;53(11):2002-8. doi: 10.1093/rheumatology/keu231. Epub 2014 Jun 6.

PMID:
24907154
17.

Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease.

Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, Karaman M, Oguz Y, Eyileten T, Vural A, Covic A, Goldsmith D, Turak O, Yilmaz MI.

Int Urol Nephrol. 2014 Aug;46(8):1619-25. doi: 10.1007/s11255-014-0730-1. Epub 2014 May 23.

PMID:
24853998
18.

The relationship between IL-10 levels and cardiovascular events in patients with CKD.

Yilmaz MI, Solak Y, Saglam M, Cayci T, Acikel C, Unal HU, Eyileten T, Oguz Y, Sari S, Carrero JJ, Stenvinkel P, Covic A, Kanbay M.

Clin J Am Soc Nephrol. 2014 Jul;9(7):1207-16. doi: 10.2215/CJN.08660813. Epub 2014 May 1.

19.

Soluble TWEAK plasma levels increase after renal transplantation and associate with the improvement of endothelial function.

Yilmaz MI, Sonmez A, Saglam M, Yaman H, Unal HU, Gok M, Cetinkaya H, Eyileten T, Oguz Y, Sari S, Yildirim AO, Vural A, Carrero JJ, Blanco-Colio LM.

Eur J Clin Invest. 2013 Dec;43(12):1250-7. doi: 10.1111/eci.12166. Epub 2013 Sep 20.

PMID:
24112080
20.

Red cell distribution width is independently related to endothelial dysfunction in patients with chronic kidney disease.

Solak Y, Yilmaz MI, Saglam M, Caglar K, Verim S, Unal HU, Gok M, Demirkaya E, Gaipov A, Kayrak M, Cetinkaya H, Eyileten T, Turk S, Vural A.

Am J Med Sci. 2014 Feb;347(2):118-24. doi: 10.1097/MAJ.0b013e3182996a96.

PMID:
23928544
21.

Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after renal transplantation.

Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Turker T, Unal HU, Gok M, Cetinkaya H, Eyileten T, Oguz Y, Caglar K, Vural A, Mallamaci F, Zoccali C.

Am J Nephrol. 2013;37(2):126-34. doi: 10.1159/000346711. Epub 2013 Jan 31.

PMID:
23391995
22.

Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients.

Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, Unal HU, Gok M, Caglar K, Oguz Y, Yenicesu M, Cetinkaya H, Eyileten T, Acikel C, Vural A, Covic A.

Am J Nephrol. 2012;36(3):228-37. Epub 2012 Aug 30.

PMID:
22948239
23.

Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.

Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C.

Am J Kidney Dis. 2012 Feb;59(2):177-85. doi: 10.1053/j.ajkd.2011.11.007. Epub 2011 Dec 2.

PMID:
22137672
24.

Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease.

Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Stenvinkel P, Yaman H, Eyileten T, Caglar K, Oguz Y, Taslipinar A, Vural A, Gok M, Unal HU, Yenicesu M, Carrero JJ.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1617-25. doi: 10.2215/CJN.10681210. Epub 2011 Jun 23.

25.

Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes.

Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M, Altun B, Yenicesu M, Carrero JJ.

Nephrol Dial Transplant. 2011 Nov;26(11):3537-43. doi: 10.1093/ndt/gfr081. Epub 2011 Mar 4.

PMID:
21378154
26.

Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.

Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M, Egido J, Altun B, Yenicesu M, Blanco-Colio LM, Carrero JJ.

Clin J Am Soc Nephrol. 2011 Apr;6(4):785-92. doi: 10.2215/CJN.09231010. Epub 2011 Feb 17.

27.

Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease.

Yilmaz MI, Sonmez A, Karaman M, Ay SA, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C.

Am J Nephrol. 2011;33(1):25-32. doi: 10.1159/000322581. Epub 2010 Dec 9.

PMID:
21150192
28.

FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease.

Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C.

Kidney Int. 2010 Oct;78(7):679-85. doi: 10.1038/ki.2010.194. Epub 2010 Jul 7.

29.

Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.

Eyileten T, Sonmez A, Saglam M, Cakir E, Caglar K, Oguz Y, Vural A, Yenicesu M, Yilmaz MI.

Nephrology (Carlton). 2010 Mar;15(2):225-9. doi: 10.1111/j.1440-1797.2009.01173.x.

PMID:
20470283
30.

Irritable bowel syndrome in haemodialysis: Prevalence, link with quality of life and depression.

Afsar B, Elsurer R, Yilmaz MI, Eyileten T, Yenicesu M.

Nephrology (Carlton). 2010 Mar;15(2):197-202. doi: 10.1111/j.1440-1797.2009.01189.x.

PMID:
20470279
31.

Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.

Yilmaz MI, Carrero JJ, Martín-Ventura JL, Sonmez A, Saglam M, Celik T, Yaman H, Yenicesu M, Eyileten T, Moreno JA, Egido J, Blanco-Colio LM.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1174-81. doi: 10.2215/CJN.01110210. Epub 2010 Apr 29.

32.

Simple renal cysts and circadian blood pressure: are they related to each other in patients with hypertension?

Afsar B, Afsar RE, Sen ST, Kirkpantur A, Eyileten T, Yilmaz MI, Caglar K.

Int Urol Nephrol. 2011 Mar;43(1):157-65. doi: 10.1007/s11255-010-9734-7. Epub 2010 Apr 13.

PMID:
20390353
33.

Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?

Yilmaz MI, Sonmez A, Saglam M, Yaman H, Cayci T, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Axelsson J.

Nephrol Dial Transplant. 2010 Oct;25(10):3250-6. doi: 10.1093/ndt/gfq159. Epub 2010 Mar 26.

PMID:
20348148
34.

Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease.

Yilmaz MI, Qureshi AR, Carrero JJ, Saglam M, Suliman ME, Caglar K, Eyileten T, Sonmez A, Oguz Y, Vural A, Yenicesu M, Axelsson J.

Am J Nephrol. 2010;31(3):214-21. doi: 10.1159/000272936. Epub 2009 Dec 31.

PMID:
20068285
35.

A case of crescentic IgA nephropathy treated with prednisolone and cyclophosphamide.

Sengul E, Eyileten T, Ozcan A, Yilmaz MI, Yenicesu M.

Hippokratia. 2009 Jul;13(3):172-4.

36.

Diffuse alveolar hemorrhage as an unusual presentation of systemic lupus erythematosus.

Sengul E, Eyıleten T, Ozcan A, Yılmaz MI, Yenıcesu M.

Rheumatol Int. 2011 Aug;31(8):1085-7. doi: 10.1007/s00296-009-1227-6. Epub 2009 Oct 27.

PMID:
19908046
37.

The relationship between hemoglobin levels and endothelial functions in diabetes mellitus.

Sonmez A, Yilmaz MI, Saglam M, Kilic S, Eyileten T, Uckaya G, Caglar K, Oguz Y, Vural A, Yenicesu M, Kutlu M, Kinalp C, Zoccali C.

Clin J Am Soc Nephrol. 2010 Jan;5(1):45-50. doi: 10.2215/CJN.05080709. Epub 2009 Oct 15.

38.

Antibody response following hepatitis B vaccination in dialysis patients: does depression and life quality matter?

Afsar B, Elsurer R, Eyileten T, Yilmaz MI, Caglar K.

Vaccine. 2009 Sep 25;27(42):5865-9. doi: 10.1016/j.vaccine.2009.07.055. Epub 2009 Aug 3.

PMID:
19654067
39.

Anti-glomerular basement membrane disease with nephrotic proteinuria.

Sengul E, Eyileten T, Ozcan A, Yilmaz MI, Yenicesu M.

Clin Nephrol. 2009 Aug;72(2):157-9. No abstract available.

PMID:
19640376
40.

Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage?

Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Oguz Y, Aslan I, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J.

Clin Transplant. 2009 Mar-Apr;23(2):241-8.

PMID:
19402217
41.

Do patients with uric acid stones exhibit abnormal circadian blood pressure--a hypothesis.

Afsar B, Yilmaz M, Eyileten T.

Nephrol Dial Transplant. 2009 Jun;24(6):2004; author reply 2004-5. doi: 10.1093/ndt/gfp082. Epub 2009 Mar 13. No abstract available.

PMID:
19286692
42.

Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease.

Yilmaz MI, Sonmez A, Saglam M, Gulec M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C.

Kidney Int. 2009 Jun;75(12):1316-1321. doi: 10.1038/ki.2009.63. Epub 2009 Mar 4.

43.

Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.

Yilmaz MI, Axelsson J, Sonmez A, Carrero JJ, Saglam M, Eyileten T, Caglar K, Kirkpantur A, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P.

Clin J Am Soc Nephrol. 2009 Mar;4(3):535-41. doi: 10.2215/CJN.04330808. Epub 2009 Feb 11.

44.

The relationship between adiponectin levels and degree of proteinuria in patients with nephrotic and non-nephrotic proteinuria.

Oguz Y, Yilmaz MI, Acikel C, Eyileten T, Caglar K, Oktenli C, Yenicesu M, Vural A.

Ren Fail. 2009;31(1):29-35. doi: 10.1080/08860220802546461.

PMID:
19142807
45.

Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease.

Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B.

Nephron Clin Pract. 2008;108(3):c233-40. doi: 10.1159/000120209. Epub 2008 Mar 11.

PMID:
18334823
46.

ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction.

Yilmaz MI, Sonmez A, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Cakir E, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J.

J Am Soc Nephrol. 2008 Feb;19(2):388-95. doi: 10.1681/ASN.2007040461. Epub 2008 Jan 16.

47.

Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin.

Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J.

Nephrol Dial Transplant. 2008 May;23(5):1621-7. doi: 10.1093/ndt/gfm828. Epub 2008 Jan 5.

PMID:
18175782
48.

Hyperbaric oxygen treatment augments the efficacy of cilazapril and simvastatin regimens in an experimental nephrotic syndrome model.

Sonmez A, Yilmaz MI, Korkmaz A, Topal T, Caglar K, Kaya A, Eyileten T, Yenicesu M, Oguz Y, Basal S, Ipcioglu OM, Vural A.

Clin Exp Nephrol. 2008 Apr;12(2):110-118. doi: 10.1007/s10157-007-0017-2. Epub 2008 Jan 5.

PMID:
18175058
49.

Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.

Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P.

Clin J Am Soc Nephrol. 2008 Jan;3(1):61-8. Epub 2007 Dec 5.

50.

Idiopathic tubulointerstitial nephritis and uveitis--'TINU syndrome'.

Eyileten T, Dede F, Yenicesu M, Celebi G, Vural A.

Nephrol Dial Transplant. 2008 Feb;23(2):771-2. Epub 2007 Nov 16. No abstract available.

PMID:
18024480

Supplemental Content

Loading ...
Support Center